Biogen gamma interferon agreement
Firm has finalized a licensing agreement with Baxter Travenol covering Immuneron (gamma interferon) for use in the treatment of cancer. A preliminary letter of intent between the two companies was signed in June ("The Pink Sheet" July 14, p. 4). The worldwide development and marketing agreement does not include West Germany and the Far East. Biogen retains rights to gamma interferon for noncancer indications.
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.